Definium Therapeutics reported positive topline data from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder on September 14, 2026, a result that matters because GAD pharmacotherapy has run on SSRIs and SNRIs for close to two decades with little change to the approved menu. A psychedelic-derived compound clearing a Phase 3 bar in anxiety would be a different kind of news entirely, and Definium now has that data in hand.
DT120 ODT is a formulated version of lysergide (LSD) built on Catalent’s Zydis fast-dissolve tablet technology, which Definium selected to improve absorption speed and reduce gastrointestinal side effects relative to conventional oral dosing. The compound acts as a partial agonist at serotonin 2A receptors, the same pathway targeted by most psychedelic-class candidates in development. The orally disintegrating format is a manufacturing and logistics choice with real clinical implications: it standardizes dosing in a drug class where absorption variability has complicated earlier trials and complicates the supervised-session model most programs require.
The 8-K filed with the SEC discloses only that the topline data are positive; the full dataset, including the primary endpoint result and any secondary measures, is attached as Exhibit 99.1 but not reproduced in the filing body. That means the specific magnitude of symptom reduction on whatever scale Panorama used remains unconfirmed until Definium publishes or presents the complete results. The GAD clinical standard that matters most to regulators is the Hamilton Anxiety Rating Scale, and whether Panorama was powered on that measure or a related instrument will shape how the FDA reads the package.
The next concrete marker to watch is whether Definium files for a pre-NDA meeting or announces a regulatory submission timeline, which would signal how much confidence the company places in the Panorama dataset as a standalone registration-enabling study.
Source link: https://www.sec.gov/Archives/edgar/data/1813814/000110465926107275/tm2625365d1_8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
